---
title: "This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275644345.md"
description: "Top Wall Street analysts have initiated coverage on several companies with bullish ratings. Guggenheim's Debjit Chattopadhyay rated Entrada Therapeutics (NASDAQ:TRDA) as Buy with a $20 target. Stifel's Laura Prendergast rated BridgeBio Oncology (NASDAQ:BBOT) as Buy with a $23 target and Olema Pharmaceuticals (NASDAQ:OLMA) with a $48 target. Goldman Sachs' Brian Lee rated Energy Fuels (AMEX:UUUU) as Buy with a $30 target. Current share prices are $10.82, $10.84, $21.76, and $23.37 respectively for these companies."
datetime: "2026-02-11T18:06:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275644345.md)
  - [en](https://longbridge.com/en/news/275644345.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275644345.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275644345.md) | [繁體中文](https://longbridge.com/zh-HK/news/275644345.md)


# This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   Guggenheim analyst Debjit Chattopadhyay initiated coverage on **Entrada Therapeutics Inc** (NASDAQ:TRDA) with a Buy rating and announced a price target of $20. Entrada Therapeutics shares closed at $10.82 on Tuesday. See how other analysts view this stock.
-   Stifel analyst Laura Prendergast initiated coverage on **BridgeBio Oncology Therapeutics, Inc.** (NASDAQ:BBOT) with a Buy rating and announced a price target of $23. BridgeBio Oncology shares closed at $10.84 on Tuesday. See how other analysts view this stock.
-   Goldman Sachs analyst Brian Lee initiated coverage on **Energy Fuels Inc**. (AMEX:UUUU) with a Buy rating and announced a price target of $30. Energy Fuels shares closed at $21.76 on Tuesday. See how other analysts view this stock.
-   Stifel analyst Laura Prendergast initiated coverage on **Olema Pharmaceuticals, Inc**. (NASDAQ:OLMA) with a Buy rating and announced a price target of $48. Olema Pharmaceuticals shares closed at $23.37 on Tuesday. See how other analysts view this stock.

Considering buying OLMA stock? Here’s what analysts think:

Photo via Shutterstock

### Related Stocks

- [Olema Pharmaceuticals, Inc. (OLMA.US)](https://longbridge.com/en/quote/OLMA.US.md)
- [Energy Fuels Inc. (UUUU.US)](https://longbridge.com/en/quote/UUUU.US.md)
- [BridgeBio Oncology Therapeutics, Inc. (BBOT.US)](https://longbridge.com/en/quote/BBOT.US.md)
- [Entrada Therapeutics, Inc. (TRDA.US)](https://longbridge.com/en/quote/TRDA.US.md)

## Related News & Research

- [Earnings Summary: Entrada Therapeutics Q4](https://longbridge.com/en/news/277041232.md)
- [BridgeBio Oncology Touts “Best in RAS” Pipeline, Highlights BBO-8520 Response and Combo Tolerability](https://longbridge.com/en/news/276975538.md)
- [Key facts: Analyst maintains $15 target for XRP; large wallets accumulate; XRPL flaw reported](https://longbridge.com/en/news/277329258.md)
- [13 Analysts Have This To Say About Mirum Pharmaceuticals](https://longbridge.com/en/news/277082071.md)
- [The Analyst Verdict: Kiniksa Pharmaceuticals In The Eyes Of 4 Experts](https://longbridge.com/en/news/276923017.md)